SCHEMBL12615970

SCHEMBL12615970

Cc1ccc(S(=O)(=O)n2cc(-c3cccc(OC(C)C)n3)c3cc(-c4nnc(N5CCC(NC(=O)O)C5)s4)ccc32)cc1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 5/20 0.51
▸ PIM3 Q86V86 5/20 0.51
▸ PIM2 Q9P1W9 5/20 0.51
▸ S1PR1 P21453 2/20 0.36
▸ FLT3 P36888 1/20 0.35
▸ PTGDR2 Q9Y5Y4 3/20 0.33
▸ PPARG P37231 1/20 0.33
▸ PPARD Q03181 1/20 0.33
▸ PPARA Q07869 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ MAPT P10636 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ PTGDR Q13258 1/20 0.32
▸ GLS O94925 2/20 0.32
▸ HTR2A P28223 1/20 0.32
▸ HTR6 P50406 1/20 0.32
▸ HRH3 Q9Y5N1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12615728 0.93 PIM1 (0.47) PIM1PIM3PIM2
SCHEMBL15844797 0.93 PIM1 (0.47) PIM1PIM3PIM2
SCHEMBL15844554 0.93 PIM1 (0.47) PIM1PIM3PIM2
SCHEMBL12614856 0.82 PIM1 (0.47) PIM1PIM3PIM2S1PR1FLT3
SCHEMBL12615465 0.79 PIM1 (0.44) PIM1PIM3PIM2L3MBTL1HTR2A
SCHEMBL12616440 0.79 PIM1 (0.45) PIM1PIM3PIM2S1PR1FLT3
SCHEMBL15844843 0.79 PIM1 (0.45) PIM1PIM3PIM2S1PR1FLT3
SCHEMBL12615758 0.74 PIM1 (0.57) PIM1PIM3PIM2L3MBTL1HTR2A
SCHEMBL12615851 0.74 PIM1 (0.42) PIM1PIM2FLT3PPARGL3MBTL1
SCHEMBL12615966 0.73 PIM1 (0.57) PIM1PIM3PIM2L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9321756-B2 Azole compounds as PIM inhibitors AMGEN INC. (US) 2016-04-26 — — US disclosed
US-20140187553-A1 Azole Compounds as PIM Inhibitors AMGEM INC. (US) 2014-07-03 — — US disclosed
EP-2688886-A1 AZOLE COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2014-01-29 — — EP disclosed
WO-2012129338-A1 AZOLE COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-09-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140187553-A1 Azole Compounds as PIM Inhibitors PIM1, PIM3, PIM2 PIM1 1/4885PIM3 2/4885PIM2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback